Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.NOVA1 Antibody (Internal)
Goat Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC-P, E |
|---|---|
| Primary Accession | P51513 |
| Reactivity | Human, Mouse, Rat, Rabbit, Monkey, Pig, Chicken, Xenopus, Bovine, Dog |
| Host | Goat |
| Clonality | Polyclonal |
| Calculated MW | 52kDa |
| Dilution | ELISA (1:64000), IHC-P (2.5 µg/ml), WB (0.01-0.03 µg/ml) |
| Other Names | RNA-binding protein Nova-1, Neuro-oncological ventral antigen 1, Onconeural ventral antigen 1, Paraneoplastic Ri antigen, Ventral neuron-specific protein 1, NOVA1 |
|---|---|
| Target/Specificity | Human NOVA1. This antibody is expected to recognise all three reported isoforms (NP_002506.2 ; NP_006480.2 ; NP_006482.1) |
| Reconstitution & Storage | Store at -20°C. Minimize freezing and thawing. |
| Precautions | NOVA1 Antibody (Internal) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | NOVA1 |
|---|---|
| Function | May regulate RNA splicing or metabolism in a specific subset of developing neurons. |
| Cellular Location | Nucleus. |
| Tissue Location | Brain. EMBL; U04840; AAA16022.1; -; mRNA EMBL; AK289639; BAF82328.1; -; mRNA EMBL; AK291022; BAF83711.1; -; mRNA EMBL; AL079343; -; NOT_ANNOTATED_CDS; Genomic_DNA EMBL; AL132716; -; NOT_ANNOTATED_CDS; Genomic_DNA EMBL; CH471078; EAW65990.1; -; Genomic_DNA EMBL; CH471078; EAW65991.1; -; Genomic_DNA EMBL; CH471078; EAW65992.1; -; Genomic_DNA EMBL; CH471078; EAW65993.1; -; Genomic_DNA EMBL; CH471078; EAW65995.1; -; Genomic_DNA EMBL; BC075038; AAH75038.1; -; mRNA EMBL; BC075039; AAH75039.1; -; mRNA EMBL; Z70771; CAA94810.1; -; mRNA CCDS; CCDS32060.1; -. [P51513-5] CCDS; CCDS32061.1; -. [P51513-4] CCDS; CCDS9635.1; -. [P51513-2] PIR; I38489; I38489 RefSeq; NP_002506.2; NM_002515.2. [P51513-4] RefSeq; NP_006480.2; NM_006489.2. [P51513-5] RefSeq; NP_006482.1; NM_006491.2. [P51513-2] UniGene; Hs.31588; - PDB; 1DT4; X-ray; 2.60 A; A=424-495 PDB; 2ANN; X-ray; 2.30 A; A=49-249 PDB; 2ANR; X-ray; 1.94 A; A=49-249 PDBsum; 1DT4; - PDBsum; 2ANN; - PDBsum; 2ANR; - ProteinModelPortal; P51513; - SMR; P51513; - BioGrid; 110919; 10 IntAct; P51513; 8 MINT; P51513; - STRING; 9606.ENSP00000438875; - iPTMnet; P51513; - PhosphoSitePlus; P51513; - BioMuta; NOVA1; - DMDM; 1709303; - EPD; P51513; - MaxQB; P51513; - PaxDb; P51513; - PeptideAtlas; P51513; - PRIDE; P51513; - ProteomicsDB; 56315; - ProteomicsDB; 56316; -. [P51513-2] ProteomicsDB; 56317; -. [P51513-3] ProteomicsDB; 56318; -. [P51513-4] TopDownProteomics; P51513-2; -. [P51513-2] Ensembl; ENST00000344429; ENSP00000342387; ENSG00000139910. [P51513-2] Ensembl; ENST00000465357; ENSP00000447391; ENSG00000139910. [P51513-5] Ensembl; ENST00000539517; ENSP00000438875; ENSG00000139910. [P51513-4] GeneID; 4857; - KEGG; hsa:4857; - UCSC; uc001wpy.4; human. [P51513-1] CTD; 4857; - DisGeNET; 4857; - EuPathDB; HostDB:ENSG00000139910.19; - GeneCards; NOVA1; - H-InvDB; HIX0037755; - HGNC; HGNC:7886; NOVA1 HPA; HPA004155; - MIM; 602157; gene neXtProt; NX_P51513; - OpenTargets; ENSG00000139910; - PharmGKB; PA31688; - eggNOG; KOG2191; Eukaryota eggNOG; ENOG410XRZD; LUCA GeneTree; ENSGT00760000119144; - HOGENOM; HOG000007833; - HOVERGEN; HBG082048; - InParanoid; P51513; - KO; K14944; - OMA; VVDFIMD; - OrthoDB; EOG091G185U; - PhylomeDB; P51513; - TreeFam; TF316981; - ChiTaRS; NOVA1; human EvolutionaryTrace; P51513; - GeneWiki; NOVA1; - GenomeRNAi; 4857; - PRO; PR:P51513; - Proteomes; UP000005640; Chromosome 14 Bgee; ENSG00000139910; - CleanEx; HS_NOVA1; - ExpressionAtlas; P51513; baseline and differential Genevisible; P51513; HS GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA GO; GO:0005730; C:nucleolus; IDA:HPA GO; GO:0005634; C:nucleus; IDA:HPA GO; GO:0003729; F:mRNA binding; IEA:Ensembl GO; GO:0003723; F:RNA binding; HDA:UniProtKB GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc GO; GO:0007626; P:locomotory behavior; TAS:ProtInc GO; GO:0000398; P:mRNA splicing, via spliceosome; IEA:Ensembl GO; GO:0051252; P:regulation of RNA metabolic process; IEA:Ensembl GO; GO:0006396; P:RNA processing; TAS:ProtInc GO; GO:0008380; P:RNA splicing; TAS:ProtInc Gene3D; 3.30.1370.10; -; 3 InterPro; IPR004087; KH_dom InterPro; IPR004088; KH_dom_type_1 InterPro; IPR036612; KH_dom_type_1_sf InterPro; IPR033086; NOVA1 PANTHER; PTHR10288:SF223; PTHR10288:SF223; 1 Pfam; PF00013; KH_1; 3 SMART; SM00322; KH; 3 SUPFAM; SSF54791; SSF54791; 3 PROSITE; PS50084; KH_TYPE_1; 3 1: Evidence at protein level; 3D-structure; Alternative splicing; Complete proteome; Nucleus; Phosphoprotein; Reference proteome; Repeat; RNA-binding CHAIN 1 510 RNA-binding protein Nova-1 /FTId=PRO_0000050116 DOMAIN 49 119 KH 1. {ECO:0000255|PROSITE- ProRule:PRU00117} DOMAIN 174 240 KH 2. {ECO:0000255|PROSITE- ProRule:PRU00117} DOMAIN 424 491 KH 3. {ECO:0000255|PROSITE- ProRule:PRU00117} MOTIF 27 43 Bipartite nuclear localization signal COMPBIAS 276 412 Ala-rich MOD_RES 157 157 Phosphoserine {ECO:0000250|UniProtKB:Q9JKN6} VAR_SEQ 88 90 Missing (in isoform 2, isoform 4 and isoform 5). /FTId=VSP_002841 VAR_SEQ 153 176 Missing (in isoform 3 and isoform 5) /FTId=VSP_002842 VAR_SEQ 177 184 VKIIVPNS -> KHNISWIS (in isoform 2) /FTId=VSP_002843 VAR_SEQ 185 510 Missing (in isoform 2) /FTId=VSP_002844 STRAND 50 57 {ECO:0000244|PDB:2ANR} HELIX 58 65 {ECO:0000244|PDB:2ANR} HELIX 67 69 {ECO:0000244|PDB:2ANR} HELIX 70 79 {ECO:0000244|PDB:2ANR} STRAND 82 85 {ECO:0000244|PDB:2ANR} STRAND 98 107 {ECO:0000244|PDB:2ANR} HELIX 109 123 {ECO:0000244|PDB:2ANR} HELIX 148 151 {ECO:0000244|PDB:2ANR} STRAND 177 182 {ECO:0000244|PDB:2ANR} HELIX 183 190 {ECO:0000244|PDB:2ANR} HELIX 192 194 {ECO:0000244|PDB:2ANR} HELIX 195 203 {ECO:0000244|PDB:2ANR} STRAND 207 210 {ECO:0000244|PDB:2ANR} STRAND 221 229 {ECO:0000244|PDB:2ANR} HELIX 230 245 {ECO:0000244|PDB:2ANR} STRAND 425 432 {ECO:0000244|PDB:1DT4} TURN 433 436 {ECO:0000244|PDB:1DT4} HELIX 437 440 {ECO:0000244|PDB:1DT4} HELIX 442 444 {ECO:0000244|PDB:1DT4} HELIX 445 454 {ECO:0000244|PDB:1DT4} STRAND 457 460 {ECO:0000244|PDB:1DT4} STRAND 472 479 {ECO:0000244|PDB:1DT4} HELIX 481 494 {ECO:0000244|PDB:1DT4} SEQUENCE 510 AA; 52056 MW; 7B9BA8B67CAB6984 CRC64; MMAAAPIQQN GTHTGVPIDL DPPDSRKRPL EAPPEAGSTK RTNTGEDGQY FLKVLIPSYA AGSIIGKGGQ TIVQLQKETG ATIKLSKLSK SKDFYPGTTE RVCLIQGTVE ALNAVHGFIA EKIREMPQNV AKTEPVSILQ PQTTVNPDRI KQTLPSSPTT TKSSPSDPMT TSRANQVKII VPNSTAGLII GKGGATVKAV MEQSGAWVQL SQKPDGINLQ ERVVTVSGEP EQNRKAVELI IQKIQEDPQS GSCLNISYAN VTGPVANSNP TGSPYANTAE VLPTAAAAAG LLGHANLAGV AAFPAVLSGF TGNDLVAITS ALNTLASYGY NLNTLGLGLS QAAATGALAA AAASANPAAA AANLLATYAS EASASGSTAG GTAGTFALGS LAAATAATNG YFGAASPLAA SAILGTEKST DGSKDVVEIA VPENLVGAIL GKGGKTLVEY QELTGARIQI SKKGEFVPGT RNRKVTITGT PAATQAAQYL ITQRITYEQG VRAANPQKVG |
Research Areas
Citations (0)
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Submit your citation using an Abgent antibody to
info@abgent.com, and receive a free "I Love Antibodies" mug.
info@abgent.com, and receive a free "I Love Antibodies" mug.
Application Protocols
Provided below are standard protocols that you may find useful for product applications.
Background
May regulate RNA splicing or metabolism in a specific subset of developing neurons.
References
Buckanovich R.J.,et al.Neuron 11:657-672(1993).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Venter J.C.,et al.Science 291:1304-1351(2001).
Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
Dmitrenko V.V.,et al.Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases.
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
$ 425.00
Cat# ALS12732
Ordering Information
United States
AlbaniaAustraliaAustriaBelgiumBosnia & HerzegovinaBrazilBulgariaCanadaCentral AmericaChinaCroatiaCyprusCzech RepublicDenmarkEstoniaFinlandFranceGermanyGreeceHong KongHungaryIcelandIndiaIndonesiaIrelandIsraelItalyJapanLatviaLithuaniaLuxembourgMacedoniaMalaysiaMaltaNetherlandsNew ZealandNorwayPakistanPolandPortugalRomaniaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSouth KoreaSpainSwedenSwitzerlandTaiwanTurkeyUnited KingdomUnited StatesVietnamWorldwideOthers
USA Headquarters
(888) 735-7227 / (858) 622-0099 or (858) 875-1900
Other Products
Shipping Information
Domestic orders (in stock items)
Shipped out the same day. Orders placed after 1 PM (PST) will ship out the next business day.
International orders
Contact your local distributors
